Circulating dopamine and C-peptide levels in fasting nondiabetic hypertensive patients: The Graz Endocrine Causes of Hypertension study

Diabetes Care

Volumn 35, Issue 8, 2012, Pages 1771-1773

  Tomaschitz, Andreas ^a   Ritz, Eberhard ^b   Kienreich, Katharina ^a   Pieske, Burkert ^a   März, Winfried ^a,c,d   Boehm, Bernhard O ^e   Drechsler, Christiane ^f   Meinitzer, Andreas ^a   Pilz, Stefan ^a,g  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c SYNLAB ACADEMY   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e UNIVERSITY OF ULM   (Germany)

^f UNIVERSITY OF WÜRZBURG   (Germany)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; C PEPTIDE; DOPAMINE; INSULIN; NORADRENALIN;

ADRENALIN BLOOD LEVEL; ADULT; ARTICLE; CONCENTRATION (PARAMETERS); DISEASE ASSOCIATION; DOPAMINE BLOOD LEVEL; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RELEASE; MAJOR CLINICAL STUDY; MALE; NORADRENALIN BLOOD LEVEL; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION;

ADULT; C-PEPTIDE; DOPAMINE; FASTING; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED;

EID: 84864386421     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-2384     Document Type: Article

References (15)

1. Goldstein DS, Holmes C. Neuronal source of plasma dopamine. Clin Chem2008;54:1864-1871
2. Quickel KE Jr, Feldman JM, Lebovitz HE. Inhibition of insulin secretion by serotonin and dopamine: species variation. Endocrinology 1971;89:1295-1302
3. Lerner RL, Porte D Jr. Epinephrine: selective inhibition of the acute insulin response to glucose. J Clin Invest 1971;50:2453-2457
4. Rubí B, Ljubicic S, Pournourmohammadi S, et al. Dopamine D2-like receptors are expressed in pancreatic beta cells and mediate inhibition of insulin secretion. J Biol Chem 2005;280:36824-36832 (Pubitemid 41587763)
5. García-Tornadú I, Ornstein AM, Chamson-Reig A, et al.Disruption of the dopamine d2 receptor impairs insulin secretion and causes glucose intolerance. Endocrinology 2010;151:1441-1450
6. Pilz S, Tomaschitz A, Stepan V, et al. Graz Endocrine Causes of Hypertension (GECOH) Study: a diagnostic accuracy study of aldosterone to active renin ratio in screening for primary aldosteronism. BMC Endocr Disord 2009;9:11
7. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2009;32(Suppl. 1):S62-S67
8. Martin G, Forte P, Luchsinger A, et al. Dopamine-induced antihypertensive effects and plasma insulin rise are blocked by metoclopramide in labetalol-treated patients. J Clin Pharmacol 1994;34:91-94 (Pubitemid 24050371)
9. Ruttimann Y, Schutz Y, Jéquier E, Lemarchand T, Chioléro R. Thermogenic and metabolic effects of dopamine in healthy men. Crit Care Med 1991;19:1030-1036
10. Shankar E, Santhosh KT, Paulose CS. Dopaminergic regulation of glucose-induced insulin secretion through dopamine D2 receptors in the pancreatic islets in vitro. IUBMB Life 2006;58:157-163 (Pubitemid 43786041)
11. de Leeuw van Weenen JE, Parlevliet ET, Maechler P, et al. The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells. Biochem Pharmacol 2010;79:1827-1836
12. Lebovitz HE. Metabolic consequences of atypical antipsychotic drugs. Psychiatr Q 2003;74:277-290 (Pubitemid 38115322)
13. Pijl H, Ohashi S, Matsuda M, et al. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care 2000;23:1154-1161 (Pubitemid 30616805)
14. Cincotta AH, Meier AH. Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. Diabetes Care 1996;19:667-670 (Pubitemid 26182986)
15. Wasada T, Kawahara R, Iwamoto Y. Lack of evidence for bromocriptine effect on glucose tolerance, insulin resistance, and body fat stores in obese type 2 diabetic patients. Diabetes Care 2000;23:1039-1040 (Pubitemid 30480053)